Can Zoetis Beat Its Big Pharma Competition?
The company announced revenue growth in its earnings call, but that doesn’t necessarily mean investors should rest easily
Novo Nordisk's Biggest Strength and Weakness
Is Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?
Merck Gets FDA Approval for Noxafil Tablets, Increases Dividend
Perhaps buoyed by optimism, Merck also raises its shareholder payout.
Is BioMarin's Vimizim Grabbing Suitors Attention?
Drug companies continue to acquire orphan drug biotechnology companies to boost pipelines. Will BioMarin's Vimizim help convince them to buy BioMarin too?